Table 5.
Multivariate Cox proportional hazards model to determine predictors of overall survival in patient treated with CDK4/6is plus ET.
| Variables | MV-HR | 95% CI | P value |
|---|---|---|---|
| Histology (compared to IDC) | |||
| ILC | 1.17 | 0.96–1.41 | 0.109 |
| Mixed | 0.98 | 0.62–1.47 | 0.949 |
| Race (compared to White) | |||
| Black | 0.90 | 0.70–1.15 | 0.754 |
| Hispanic | 1.08 | 0.84–1.37 | 0.504 |
| ET backbone (compared to AI) | |||
| Fulvestrant | 1.15 | 0.99–1.33 | 0.055 |
CDK4/6is cyclin-dependent kinase 4 and 6 inhibitors, ET endocrine therapy, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, Mixed mixed invasive ductal and lobular carcinoma, AI aromatase inhibitor, MV-HR multivariate hazard ratio, CI confidence interval.